Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series
British Journal of Haematology · 2026-06 · 208 (6) · 2265-2268
DOI: 10.1111/bjh.70510 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 29.04.2026. Verfasst von Gráinne Marron und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sir Charles Gairdner Hospital, Perth, Western Australia, Australia. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
ORCID-Profile: Gráinne Marron
Zitieren
APA
Marron, G., Warrier, N., Chan, K., & Augustson, B. (2026). Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series. British Journal of Haematology, 208(6), 2265-2268. https://doi.org/10.1111/bjh.70510
Vancouver
Marron G, Warrier N, Chan K, Augustson B. Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series. British Journal of Haematology. 2026;208(6):2265-2268. doi:10.1111/bjh.70510
BibTeX
@article{Marron2026,
author = {Marron, Gráinne and Warrier, Niklesh and Chan, Kelvin and Augustson, Bradley},
title = {Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {6},
pages = {2265--2268},
doi = {10.1111/bjh.70510}
}
EUVIMED